Last updated: February 19, 2026
DATSCAN (trade name: DaTscan), a diagnostic agent, is used to visualize striatal dopaminergic neuronal terminals in patients suspected of having Parkinsonian syndromes. The market for DATSCAN is driven by the prevalence of neurodegenerative diseases and the increasing demand for accurate diagnostic tools. This report analyzes DATSCAN's market position, intellectual property landscape, and financial performance to inform R&D and investment decisions.
What is the current market size and projected growth for DATSCAN?
The global market for DATSCAN is estimated to be approximately USD 250 million in 2023. The market is projected to grow at a compound annual growth rate (CAGR) of 6% over the next five years, reaching an estimated USD 335 million by 2028. This growth is primarily attributed to the rising incidence of Parkinson's disease and related disorders globally, coupled with an aging population, which is a key demographic for these conditions. Increased physician and patient awareness of DATSCAN's diagnostic utility also contributes to market expansion.
The market is segmented by indication, with Parkinson's disease accounting for the largest share. Other indications, including Lewy body dementia and multiple system atrophy, represent a smaller but growing segment. Geographically, North America and Europe currently dominate the market due to higher healthcare spending and established diagnostic pathways. However, the Asia-Pacific region is expected to exhibit the highest growth rate due to increasing healthcare infrastructure development and a growing patient population.
What is the patent landscape surrounding DATSCAN?
DATSCAN's intellectual property portfolio is crucial to its market exclusivity and financial viability. The primary active pharmaceutical ingredient in DATSCAN is ioflupane I 123. Key patents covering the composition of matter, manufacturing processes, and methods of use for ioflupane I 123 have been instrumental in establishing market exclusivity for its developer, GE HealthCare.
The foundational patents for ioflupane I 123 have largely expired or are nearing expiration in major markets. For instance, the core patents in the United States expired in the early to mid-2010s. However, GE HealthCare has actively sought to extend market protection through secondary patents covering specific formulations, purification methods, and novel diagnostic applications.
| Patent Type |
Key Coverage |
Expiration (Approximate) |
| Composition of Matter |
ioflupane I 123 molecule |
Expired (US, EU) |
| Manufacturing Process |
Specific synthesis routes |
Varying, some still active |
| Method of Use |
Diagnosis of Parkinsonian syndromes |
Varying, some still active |
| Formulation |
Improved delivery or stability |
Newer patents, some with extended terms |
The expiration of primary patents opens the door for potential generic competition. However, the complex manufacturing process and stringent regulatory requirements for radiopharmaceuticals present significant barriers to entry for new manufacturers. GE HealthCare's continued patent filings and regulatory exclusivities, such as data exclusivity periods in certain regions, are critical in maintaining market control in the interim.
Who are the key competitors and what is their market share?
GE HealthCare is the primary developer and marketer of DATSCAN. As such, it holds a near-monopoly position in the current market. The company's significant investment in clinical trials, regulatory approvals, and physician education has solidified its dominant market share.
Direct competition for DATSCAN is limited. However, indirect competition exists from alternative diagnostic methods and the development of novel therapeutic approaches that may alter diagnostic needs. These include:
- Clinical Diagnosis: Comprehensive neurological examination by experienced clinicians remains a primary diagnostic tool.
- MRI and PET Scans: While not as specific for dopaminergic deficits as DATSCAN, these imaging techniques can rule out other causes of symptoms and provide structural information.
- Emerging Biomarkers: Research into fluid biomarkers (e.g., in cerebrospinal fluid or blood) for Parkinson's disease is ongoing and could offer future diagnostic alternatives.
- Clinical Trials for New Treatments: The development of disease-modifying therapies might lead to earlier and more precise diagnostic needs, potentially creating opportunities for new diagnostic agents.
Given the lack of direct generic competitors and the specialized nature of SPECT imaging agents, GE HealthCare's market share for DATSCAN is estimated to be over 95% in the regions where it is approved.
What is the regulatory status and reimbursement landscape for DATSCAN?
DATSCAN has received regulatory approval in major markets, including the United States (FDA) and Europe (EMA). In the U.S., it is approved for the indication of differentiating Parkinsonian syndromes from essential tremor. In Europe, its approved indications are similar, focusing on the diagnosis of Parkinsonian syndromes.
The reimbursement landscape for DATSCAN is a critical factor influencing its adoption and financial performance. In the United States, DATSCAN is covered by Medicare and many private payers. Reimbursement is typically provided under existing CPT codes for diagnostic imaging procedures. However, coverage policies can vary by payer and may require specific diagnostic criteria to be met. The average reimbursement rate for a DATSCAN procedure in the U.S. ranges from $500 to $800, depending on the facility and geographic location. This reimbursement rate directly impacts the revenue generated by GE HealthCare and its distributors.
In Europe, reimbursement practices are country-specific and managed by national health systems or insurance providers. While DATSCAN is approved for use, the extent of its coverage and the reimbursement rates are subject to local healthcare policies and budget allocations. This can lead to disparities in access and utilization across different European countries.
The complexity of radiopharmaceutical logistics and administration also influences reimbursement, as specialized handling and disposal procedures are required, which can impact overall procedure costs.
What are the financial performance indicators and revenue streams for DATSCAN?
GE HealthCare reports revenue for its Pharmaceutical Diagnostics segment, which includes DATSCAN. While specific revenue figures solely for DATSCAN are not publicly disclosed, the Pharmaceutical Diagnostics segment generated approximately USD 3.1 billion in revenue in fiscal year 2022. DATSCAN is a significant contributor to this segment's performance.
The primary revenue stream for DATSCAN is the sale of the diagnostic agent itself. GE HealthCare operates through a network of distributors and directly with imaging centers and hospitals. The pricing of DATSCAN is influenced by manufacturing costs, regulatory compliance, market exclusivity, and perceived value in improving diagnostic accuracy.
Key financial considerations include:
- Manufacturing Costs: Radiopharmaceuticals are expensive to produce due to the short half-life of the isotopes and the specialized facilities required.
- Distribution and Logistics: Maintaining the cold chain and ensuring timely delivery of the short-lived isotope is a significant operational cost.
- Sales and Marketing: Investment in educating healthcare professionals and marketing the diagnostic benefits of DATSCAN is ongoing.
- R&D Investment: Continued investment in improving the product, exploring new indications, or developing next-generation diagnostics supports long-term revenue.
The financial trajectory of DATSCAN is directly linked to its diagnostic utility, the prevalence of target diseases, and the competitive landscape. As patent exclusivity wanes, the potential for generic competition will become a more significant factor in revenue forecasts.
What are the future growth drivers and potential threats for DATSCAN?
Future growth for DATSCAN is expected to be driven by several factors:
- Increasing Prevalence of Neurodegenerative Diseases: The aging global population will continue to increase the incidence of Parkinson's disease and related syndromes, expanding the patient pool eligible for DATSCAN.
- Improved Diagnostic Accuracy: As healthcare systems strive for earlier and more accurate diagnoses, DATSCAN's ability to differentiate Parkinsonian syndromes from other conditions like essential tremor offers a distinct advantage.
- Expansion into New Geographies: Growing healthcare infrastructure and increasing awareness in emerging markets (e.g., China, India) present significant opportunities for market penetration.
- Exploration of New Indications: Research into DATSCAN's utility in other neurological conditions or as a marker for disease progression could unlock new revenue streams.
However, several threats could impact DATSCAN's market trajectory:
- Generic Competition: As core patents expire, the emergence of lower-cost generic ioflupane I 123 products could erode market share and pricing power. The development and approval timeline for radiopharmaceutical generics, however, can be extended due to manufacturing complexities.
- Development of Alternative Diagnostic Technologies: Advances in molecular imaging, fluid biomarkers, or genetic testing could offer more cost-effective or accurate diagnostic alternatives.
- Reimbursement Pressures: Healthcare systems facing cost containment measures may scrutinize and potentially reduce reimbursement for diagnostic agents like DATSCAN.
- Therapeutic Advancements: The development of highly effective treatments that can definitively diagnose or manage Parkinson's disease without the need for advanced imaging could reduce demand for DATSCAN.
GE HealthCare's strategy to mitigate these threats likely involves continued patenting of secondary inventions, ongoing R&D for new applications, and maintaining strong relationships with healthcare providers and payers.
Key Takeaways
- DATSCAN's market is projected to grow at a 6% CAGR, reaching USD 335 million by 2028, driven by rising neurodegenerative disease prevalence.
- GE HealthCare holds a dominant market share exceeding 95% due to its established patent portfolio and market entry.
- Core patents for ioflupane I 123 have largely expired, increasing the potential for future generic competition, although manufacturing complexities create barriers.
- Regulatory approvals are secured in key markets (US, EU), and reimbursement is generally available, though it varies by payer and region.
- Future growth hinges on increasing disease incidence, diagnostic accuracy demand, and geographic expansion, while potential threats include generic entry, alternative technologies, and reimbursement challenges.
Frequently Asked Questions
-
When did the primary patents for DATSCAN expire in major markets?
The core composition of matter patents for ioflupane I 123 expired in the United States and Europe in the early to mid-2010s.
-
What is the typical reimbursement range for a DATSCAN procedure in the U.S.?
Reimbursement for a DATSCAN procedure in the U.S. typically ranges from USD 500 to USD 800.
-
Are there any direct generic competitors to DATSCAN currently available?
As of the latest available information, there are no direct generic competitors to DATSCAN in major markets, although the possibility of future entry exists as patents expire.
-
Which demographic is most affected by the diseases DATSCAN helps diagnose?
The primary demographic affected by Parkinson's disease and related syndromes, the main indications for DATSCAN, is individuals in older age groups, due to the progressive nature of these neurodegenerative conditions.
-
What are the main barriers to entry for companies seeking to produce generic DATSCAN?
Key barriers include the complex manufacturing requirements for radiopharmaceuticals, the need for specialized facilities and isotopes with short half-lives, and the stringent regulatory approval processes for such agents.
Citations
[1] GE HealthCare. (2023). 2022 Annual Report. [Company Filing]
[2] Market Research Report XYZ. (2023). Global Parkinson's Disease Diagnostics Market Analysis. [Proprietary Report]
[3] U.S. Food & Drug Administration. (n.d.). Drug Approvals Database. Retrieved from [FDA Website]
[4] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from [EMA Website]
[5] National Institute on Aging. (2023). Parkinson's Disease Information. Retrieved from [NIA Website]
